You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞銀下調國藥(01099.HK)目標價至28元 評級「買入」
阿思達克 03-24 10:34
瑞銀髮表研究報告指出,國藥(01099.HK)去年收入5,211億元人民幣,純利131億元人民幣,分別按年增長14.2%及8%。公司去年下半年收入增長7.6%,較上半年收入增長22.3%爲低。 該行提及,國藥管理層預期2022財年增長穩定,主要由於成立創新中心,引領營銷解決方案、商業保險和互聯網醫院業務發展;於縣域等分級市場,延伸覆蓋全生命週期產品營銷模式;全週期供應鏈服務。管理層另預計近年來自藥品集中採購的影響近年將維持不變,但基於業務轉型,估計下行壓力或會逐漸緩解。 瑞銀維持對國藥「買入」評級,目標價由30元下調至28元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account